Melbourne, Nov 11, 2014 - (ABN Newswire) - Medical technology company Rhinomed Limited (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its sport technology the Turbine(TM) to receive the CE Mark.
Conforming to the regulatory and manufacturing requirements necessary to receive a CE Mark opens the way for the Turbine to be marketed directly to European consumers, as well to consumers in the four member states of the European Free Trade Association and in Turkey.
The Turbine(TM) is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a valuable to solution to dyspnea (breathlessness) during aerobic exercise.
CEO Michael Johnson said "This is an important step in our plans to take the Tur bine technology to the one of the world's largest sports and exercise markets. Having successfully registered the Turbine with the US FDA authority earlier this year, complying with the requirements necessary to gain a CE Mark was vital. Our team is focused on building our global sport business and this allows a much wider range of discussions with European based retailers and wholesalers."
The quality control systems and processes the company has in place not only ensures the Turbine complies with the requirements of American and European regulatory authorities, but will be leveraged to ensure the forthcoming OTC snoring product can achieve registration in these important global markets as well.
About the Turbine(TM)
The Turbine(TM) is a revolutionary respiratory technology designed specifically for the sport market. The Turbine delivers an average increase of 38% more airflow through the nasal passages. The Turbine(TM) product range has bee n designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training. You can purchase a turbine by visiting www.theturbine.com
WEB: Turbine Achieves CE Mark Registration
About: Rhinomed Limited
Rhinomed is a leading medical technology company developing innovative nasal, respiratory and nasal drug delivery technologies, focused on the continual improvement of the efficiency of the human engine. Rhinomed's BreatheAssist technology platform seeks to enhance the function of the nose and its role in how you breathe – while awake, when asleep, during exercise – and the way your body keeps you healthy and happy. Rhinomed is public company and is listed on the Australian Stock Exchange (ASX) where our code is (ASX:RNO). The company is headquartered in Melbourne, Australia.
Help employers find you! Check out all the jobs and post your resume.
Conforming to the regulatory and manufacturing requirements necessary to receive a CE Mark opens the way for the Turbine to be marketed directly to European consumers, as well to consumers in the four member states of the European Free Trade Association and in Turkey.
The Turbine(TM) is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a valuable to solution to dyspnea (breathlessness) during aerobic exercise.
CEO Michael Johnson said "This is an important step in our plans to take the Tur bine technology to the one of the world's largest sports and exercise markets. Having successfully registered the Turbine with the US FDA authority earlier this year, complying with the requirements necessary to gain a CE Mark was vital. Our team is focused on building our global sport business and this allows a much wider range of discussions with European based retailers and wholesalers."
The quality control systems and processes the company has in place not only ensures the Turbine complies with the requirements of American and European regulatory authorities, but will be leveraged to ensure the forthcoming OTC snoring product can achieve registration in these important global markets as well.
About the Turbine(TM)
The Turbine(TM) is a revolutionary respiratory technology designed specifically for the sport market. The Turbine delivers an average increase of 38% more airflow through the nasal passages. The Turbine(TM) product range has bee n designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training. You can purchase a turbine by visiting www.theturbine.com
WEB: Turbine Achieves CE Mark Registration
About: Rhinomed Limited
Rhinomed is a leading medical technology company developing innovative nasal, respiratory and nasal drug delivery technologies, focused on the continual improvement of the efficiency of the human engine. Rhinomed's BreatheAssist technology platform seeks to enhance the function of the nose and its role in how you breathe – while awake, when asleep, during exercise – and the way your body keeps you healthy and happy. Rhinomed is public company and is listed on the Australian Stock Exchange (ASX) where our code is (ASX:RNO). The company is headquartered in Melbourne, Australia.
Help employers find you! Check out all the jobs and post your resume.
